Live from the NIH registry
Studies recruiting near St. Paul right now
Top 25 of 1,073 recruiting studies, sorted by proximity — each links to its official registry page
CIBMTR Research Database
Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation
N/A
Observational 99,999,999 participants sought
Center for International Blood and Marrow Transplant Research — Minneapolis, Minnesota (8.1 mi)
· Sponsor: Center for International Blood and Marrow Transplant Research
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 2
Interventional 81 participants sought
Regions Hospital — Saint Paul, Minnesota (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Children's Hospitals and Clinics of Minnesota - Minneapolis — Minneapolis, Minnesota (8.1 mi)
· Sponsor: National Cancer Institute (NCI)
Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform
Any Solid Oral Medication
N/A
Interventional 200 participants sought
Allina — Minneapolis, Minnesota (8.1 mi)
· Sponsor: Dosentrx Ltd.
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Lymphoma, Large B-Cell, Diffuse
Phase 2
Interventional 594 participants sought
Minnesota Oncology Hematology (MNO) ( Site 8004) — Burnsville, Minnesota (15.1 mi)
· Sponsor: Merck Sharp & Dohme LLC
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
Niemann-Pick Type C Disease, GM1 Gangliosidosis
Phase 3
Interventional 147 participants sought
University of Minnesota Medical School — Minneapolis, Minnesota (8.1 mi)
· Sponsor: Azafaros B.V.
Vaped Phenanthrene
Former Smoker, Non-Smoker
N/A
Interventional 100 participants sought
University of Minnesota — Minneapolis, Minnesota (8.1 mi)
· Sponsor: University of Minnesota
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
Immunoglobulin A Nephropathy (IgAN)
Phase 2
Interventional 32 participants sought
Inter Med Consultants — Edina, Minnesota (12.7 mi)
· Sponsor: Novartis Pharmaceuticals
Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation
Severe Tricuspid Regurgitation
N/A
Interventional 1,186 participants sought
Abbott Northwestern Hospital — Minneapolis, Minnesota (8.1 mi)
· Sponsor: Medtronic Cardiovascular
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Phase 1
Interventional 694 participants sought
M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200 — Minneapolis, Minnesota (8.1 mi)
· Sponsor: AbbVie
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Neuroblastoma
Phase 2
Interventional 93 participants sought
Children's Hospital and Clinics of Minnesota — Minneapolis, Minnesota (8.1 mi)
· Sponsor: Giselle Sholler
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Limited Stage Small Cell Lung Cancer
Phase 2
Interventional 250 participants sought
Minnesota Oncology Hematology — Maple Grove, Minnesota (19.2 mi)
· Sponsor: SCRI Development Innovations, LLC
Waveform Capnography Compared to Colorimetric Carbon Dioxide Detection During Tracheal Intubation of Critically Ill Adults
Acute Respiratory Failure
N/A
Observational 2,092 participants sought
Regions Hospital — Saint Paul, Minnesota (0.6 mi)
· Sponsor: Brian Driver
Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems
Peripheral Neuropathies, Peripheral Neuropathy Due to Chemotherapy
N/A
Interventional 200 participants sought
Fairview Frontiers — Saint Paul, Minnesota (0.6 mi)
· Sponsor: RxFunction Inc.
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3
Interventional 540 participants sought
Minnesota Oncology Hematology, P.A. — Minneapolis, Minnesota (8.1 mi)
· Sponsor: Relay Therapeutics, Inc.
ELEVATE High-Risk PCI Pivotal Study
High-Risk Percutaneous Coronary Intervention (High-risk PCI)
N/A
Interventional 290 participants sought
Minneapolis Heart Institute — Minneapolis, Minnesota (8.1 mi)
· Sponsor: Magenta Medical Ltd.
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
N/A
Interventional 400 participants sought
International Diabetes Center — Minneapolis, Minnesota (8.1 mi)
· Sponsor: Medtronic MiniMed, Inc.
A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis
Neurotrophic Keratitis
Phase 2
Interventional 54 participants sought
Minnesota Eye Consultants — Minneapolis, Minnesota (8.1 mi)
· Sponsor: TearSolutions, Inc.
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Neovascular Age-related Macular Degeneration
Phase 4
Interventional 188 participants sought
VitreoRetinal Surgery, PLLC. — Minneapolis, Minnesota (8.1 mi)
· Sponsor: Genentech, Inc.
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Phase 3
Interventional 428 participants sought
Regions Hospital — Saint Paul, Minnesota (0.6 mi)
· Sponsor: NRG Oncology
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
Phase 1
Interventional 198 participants sought
M Health Fairview Masonic Cancer Clinic - Clinics and Surgery Center — Minneapolis, Minnesota (8.1 mi)
· Sponsor: Bayer
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis
Phase 2
Interventional 168 participants sought
DaVita Clinical Research Edina — Edina, Minnesota (12.7 mi)
· Sponsor: R1 Therapeutics
Optimizing Transcranial Magnetic Stimulation for Stimulant Use Disorder
Stimulant Use Disorder
Phase 1
Interventional 50 participants sought
University of Minnesota — Minneapolis, Minnesota (8.1 mi)
· Sponsor: University of Minnesota
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma
Phase 2
Interventional 40 participants sought
Ohio State University-Telemedicine — Minneapolis, Minnesota (8.1 mi)
· Sponsor: Sameek Roychowdhury
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
Phase 3
Interventional 600 participants sought
Research Site — Minneapolis, Minnesota (8.1 mi)
· Sponsor: AstraZeneca